随着新冠疫苗销量减少，BioNTech裁员超过1800人

2026-05-06 01:17

BioNTech (BNTX) will lay off 1,860 employees in manufacturing positions and refocus its efforts on its oncology pipeline in the face of plummeting revenue from its COVID-19 vaccine.
The German biotech said three manufacturing locations in Germany would shutter by the end of 2027. A site in Singapore will close in Q1 2027.
The company noted that it is exploring divestment options, such as a partial or total sale.
BioNTech projects annual cost savings of €500 by 2029 based on full implementation of the cost-cutting measures.
In Q1, the company's revenue dropped to €118.1 million compared to €182.8 in the year-ago period, due to dwindling COVID-19 vaccine sales. Those shots are marketed with Pfizer (PFE)
Non-GAAP EPS of -€1.95 compares to -€1.79 in Q1 2025.
The company noted that its board plans to authorize a share repurchase program up to $1B over the next year.
BioNTech is now banking its future on its oncology pipeline. This year the biotech is expected to release data on six late-stage candidates, including immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies.

More on BioNTech